ABSTRACT Background: The use of calcium supplements to prevent declines in bone mineral density and fractures is widespread in the United States, and thus reports of elevated cardiovascular disease (CVD) risk in users of calcium supplements are a major public health concern. Any elevation in CVD risk with calcium supplement use would be of particular concern in individuals with type 2 diabetes (T2D) because of increased risks of CVD and fractures observed in this population. Objective: In this study, we examined associations between calcium intake from diet and supplements and measures of subclinical CVD (calcified plaque in the coronary artery, carotid artery, and abdominal aorta) and mortality in individuals affected by T2D. Design: We performed a cross-sectional analysis in individuals affected by T2D from the family-based Diabetes Heart Study (n = 720). Results: We observed no significant associations of calcium from diet or supplements with any of our measures of calcified plaque, and no greater mortality risk was observed with increased calcium intake. Instead, calcium supplement use was modestly associated with reduced all-cause mortality in women (HR: 0.62; 95% CI: 0.42, 0.92; P = 0.017). Conclusion: Our results do not support a substantial association between calcium intake from diet or supplements and CVD risk in individuals with T2D.
INTRODUCTION
Patients with type 2 diabetes (T2D) 4 have significantly increased risk of cardiovascular disease (CVD); mortality rates from heart disease are $2-fold higher in individuals with T2D, with CVD accounting for as much as 65% of all-cause mortality in T2D patients (1) . Individuals with T2D also have elevated risk of fracture (2) , although T2D is not thought to be associated with declines in bone mineral density (BMD) (3) (4) (5) . Calcium supplementation may increase BMD and modestly reduce risk of fracture (6) . The use of calcium supplements is widespread, particularly in postmenopausal women (7) . However, several recent studies have raised concerns that calcium supplementation may lead to elevated risk of CVD, in particular higher risk of myocardial infarction (MI) (8) (9) (10) (11) (12) . Elevated risk of both fractures and CVD in individuals with T2D makes potential increases in CVD risk in individuals who are taking calcium supplements of particular concern; however, to our knowledge, potential associations between calcium intake from diet and supplements and CVD risk have not previously been examined in a cohort of T2D patients.
It has been suggested that the potential negative impacts of calcium supplements on CVD risk may be mediated by vascular calcification, which is an important measure of subclinical CVD risk, the regulation of which has many links to osteogenesis and bone physiology (10, 13) . However, a recent report showed no impact of calcium intake from diet and supplements on coronary artery calcified plaque (CAC) (14) . In the current study, we evaluated relations between calcium intake from diet and supplements and subclinical CVD as assessed by CAC, with a specific focus on patients with T2D at elevated CVD risk. In addition, the analysis was extended to evaluate potential associations of calcium intake with calcified plaque in multiple vascular beds and with all-cause and CVD mortality.
SUBJECTS AND METHODS

Study design and sample
Diabetes Heart Study (DHS) participants were recruited from 1998 through 2005 from outpatient internal medicine and endocrinology clinics and the community in Western North Carolina. Siblings concordant for T2D without advanced renal insufficiency were recruited. Ascertainment and recruitment have been described in detail previously (15) (16) (17) (18) . T2D was defined as diabetes that developed after the age of 35 y and treated with changes in diet and exercise or oral agents in the absence of initial treatment solely with insulin and without historical evidence of ketoacidosis. Diabetes diagnosis was confirmed by the measurement of fasting glucose and glycated hemoglobin. Analyses described in this study included all self-described European American individuals with T2D from the DHS with food-frequency questionnaire data, which included, in total, 720 individuals from 339 DHS families (see Supplementary Figure 1 under "Supplemental data" in the online issue).
Study protocols were approved by the Institutional Review Board at Wake Forest School of Medicine, and all participants provided written informed consent. Participant examinations were conducted in the General Clinical Research Center of the Wake Forest Baptist Medical Center. Examinations included interviews for medical history and health behaviors, anthropometric measures, assessment of resting blood pressure, electrocardiography, fasting blood sampling for laboratory analyses, and spot urine collection. Standard laboratory analyses were performed, including the assessment of fasting glucose, glycated hemoglobin, total cholesterol, HDL, and triglycerides. LDL concentrations were calculated by using Friedewald's equation; LDL concentrations were considered valid for participants whose triglyceride concentrations were ,796 mg/dL (n = 4 individuals excluded on the basis of triglyceride concentrations). Individuals were considered hypertensive if they were prescribed an antihypertensive medication or had blood pressure measurements that exceeded 140 mm Hg (systolic) or 90 mm Hg (diastolic). Measures of calcified atherosclerotic plaque by computed tomography (CT) included CAC as the sum of the left main, left anterior descending, circumflex, posterior descending, and right coronary arteries, carotid artery calcified plaque (CarCP) as the sum of the right and left common, bulb, and internal, and abdominal aortoiliac calcified plaque (AACP) as the sum of the infrarenal, right, and left common iliac segments. CT scans were performed on multidetector CT scanners with cardiac gating in chest and helical acquisitions in the abdomen. Calcium scores were measured as previously described and validated (19, 20) . Intakes of calcium and vitamin D from diet and supplements were determined by using a self-administered Block food-frequency questionnaire (21) .
Mortality was assessed for all DHS participants by using the National Social Security Death Index maintained by the US Social Security Administration. For deceased participants, the length of follow-up was determined from the date of initial study visit to the date of death. For all other participants, the length of follow-up was determined from the date of the initial study visit to the end of 2012. Copies of death certificates were obtained from county Vital Records Offices to determine the cause of death. The cause of death was categorized on the basis of these death certificates as CVD mortality (MI, congestive heart failure, cardiac arrhythmia, sudden cardiac death, peripheral vascular disease, and stroke) or as mortality from cancer, infection, end-stage renal disease, accidental, or other causes (including obstructive pulmonary disease, pulmonary fibrosis, liver failure, and Alzheimer disease). The association with mortality was assessed for both all-cause mortality and CVD mortality.
Statistical analysis
For statistical analyses, continuous variables were transformed as necessary to an approximate normality. For our analyses of vascular calcified plaque, we used the ln of (CAC + 1) and (CarCP + 1) and the square root of (AACP + 10). Dietary calcium and vitamin D intakes were adjusted for the total energy intake by using a residual method as suggested by Willett et al (22) . Total calcium and dietary calcium intakes were considered ordinal (4 quartiles) variables as was calcium intake from supplements [divided into milligramintake ranges (0, 1-500, and .500 mg) similar to those used by Samelson et al (14) ]. Quartile 1 for energy-adjusted total calcium intake for women ranged from 216 to 614.2 mg, quartile 2 ranged from 614.3 to 851 mg, quartile 3 ranged from 858 to 2098 mg, and quartile 4 ranged from 2106 to 5350 mg. Quartile 1 for energyadjusted dietary calcium intake for women ranged from 216 to 484 mg, quartile 2 ranged from 487 to 635 mg, quartile 3 ranged from 638 to 834 mg, and quartile 4 ranged from 837 to 3090 mg. Quartile 1 for energy-adjusted total calcium intake for men ranged from 280 to 600 mg, quartile 2 ranged from 601 to 783 mg, quartile 3 ranged from 784 to 1039 mg, and quartile 4 ranged from 1044 to 3212 mg. Quartile 1 for energy-adjusted dietary calcium intake for men ranged from 263 to 531 mg, quartile 2 ranged from 534 to 681.8 mg, quartile 3 ranged from 682.1 to 829 mg, and quartile 4 ranged from 831 to 1601 mg.
Relations between calcium intake ranges and CAC, CarCP, and AACP were examined by using marginal models with generalized estimating equations. Models accounted for the familial correlation by using a sandwich estimator of the variance under an exchangeable correlation. Relations between calcium intake ranges and both allcause mortality and CVD mortality were examined by using Cox proportional hazards models with sandwich-based variance estimation because of the inclusion of related individuals in the study. Associations were adjusted for covariates including age, total energy intake (kcal), BMI (in kg/m 2 ), smoking (never, past, or current), any alcohol consumption, energy-adjusted total vitamin D intake from diet and supplements (IU), use of lipid-lowering medications, calcium intake from supplements (mg), energy-adjusted dietary calcium intake (mg), menopause status, and estrogen use as indicated, similar to the analysis performed by Samelson et al (14) . Individuals with missing data for outcome variables or covariates were excluded from relevant models (see Supplementary Figure 1 under "Supplemental data" in the online issue). Of 360 women included in these analyses, 18 women had missing CAC, 26 women had missing CarCP, 100 women had missing AACP, one woman had missing smoking status, one woman had missing mortality status, and 30 women had missing menopause status. Of 360 men included in these analyses, 18 men had missing CAC, 17 men had missing CarCP, 88 men had missing AACP, and one man had missing smoking status. Data were available for all participants for all other outcomes and covariates assessed. All analyses were performed with SAS 9.3 software (SAS Institute).
RESULTS
The goal of this study was to analyze associations between calcium intake from diet and supplements and CVD risk in participants with T2D from the DHS. We assessed relationships between calcium intake and both subclinical CVD and mortality risk.
Clinical characteristics of 720 European American individuals with T2D included in this study stratified by both total calcium intake quartile and sex are summarized in Table 1 . As expected for a cohort affected by T2D, most individuals were overweight Relations between calcium intake quartiles and demographic variables were examined by using marginal models with generalized estimating equations. CVD, cardiovascular disease; DHS, Diabetes Heart Study.
or obese, and the cohort had high rates of dyslipidemia and hypertension, a high burden of vascular calcified plaque, and a high rate of previous CVD events. Few measures differed across energy-adjusted total calcium intake quartiles, although age, prevalence of alcohol consumption, and use of lipid-lowering medications (mainly statins) differed significantly in men. These factors were all considered covariates in fully adjusted models for vascular calcified plaque and mortality. All models were stratified by sex. We first assessed relations between calcium intake from diet and supplements and measures of vascular calcified plaque. In minimally adjusted models that accounted for age and total energy intake only, neither total energy-adjusted calcium intake nor calcium intake from diet or supplements was significantly associated with any vascular calcified plaque measure (CAC, CarCP, and AACP) (see Supplementary Table  1 under "Supplemental data" in the online issue). Similarly, in models adjusted for age, total energy intake, BMI, smoking, alcohol consumption, energy-adjusted total vitamin D intake from diet and supplements, use of lipid-lowering medications, calcium intake from supplements or dietary calcium intake where appropriate, and, in women, menopause status and estrogen use, no association between total energyadjusted calcium intake or calcium intake from diet or supplements and any measure of vascular calcified plaque was observed ( Table 2) .
We also assessed associations between calcium intake and both all-cause and CVD mortality ( Table 3) . We analyzed both minimally adjusted models, which were adjusted only for age and total energy intake (model 1), and more fully adjusted models, which were further adjusted for BMI, smoking, alcohol consumption, energy-adjusted total vitamin D intake from diet and supplements, use of lipid-lowering medications, calcium intake from supplements or dietary calcium intake where appropriate, and, in women, menopause status and estrogen use (model 2). For model 1, we observed a modest protective effect of increased supplemental calcium consumption on all-cause mortality in women (HR for all-cause mortality for each increase in calcium supplement use tertile: 0.61; 95% CI: 0.46, 0.83; P = 0.001). For CVD mortality, modest protective effects were also observed in both women (HR for CVD mortality: 0.59; 95% CI: 0.37, 0.94; P = 0.026) and men (HR for CVD mortality: 0.65; 95% CI: 0.43, 0.98; P = 0.042). These associations were attenuated in the more fully adjusted model 2, with only the association of calcium supplementation with reduced all-cause mortality in women remaining nominally significant (HR for all-cause mortality: 0.62; 95% CI: 0.42, 0.92; P = 0.017).
DISCUSSION
Studies have raised concerns that calcium supplementation may have the unintended negative consequence of increasing CVD risk (8) (9) (10) (11) (12) . Any increase of CVD risk in patients with T2D would be of particular concern because of their already elevated risk of CVD (1); to our knowledge, this is the first analysis of the potential negative CVD impacts of calcium intake that focused specifically on individuals affected by T2D. CAC, which is a measure of subclinical CVD, has been shown in the DHS and other cohorts to be a strong independent predictor of CVD events and mortality (23) (24) (25) (26) (27) (28) (29) (30) , with individuals affected by diabetes tending to have higher CAC (31) . The statistical power is increased for the analysis of continuous traits such as vascular calcified plaque compared with event data, and it has also been proposed that associations of calcium intake with CVD are mediated through vascular calcification (10) , highlighting the suitability of our vascular calcified plaque measures for the assessment of potential negative CVD impacts of calcium intake. We replicated the lack of impact of calcium from diet and supplements on CAC previously observed in a general population cohort (14) in patients with T2D. In addition, we did not find any evidence of negative CVD impacts of calcium intake in our analyses of CarCP, AACP, and mortality. CAC is the most commonly assessed form of vascular calcified plaque (14, 32, 33) ; however, different risk factors may contribute to calcification in different vascular beds (34, 35) , highlighting the importance of our additional analysis of AACP and CarCP.
Previous analyses of CAC, notably the analysis in a largely nondiabetic population from the Framingham Offspring Study, have also shown no significant impact of calcium intake on CAC burden (14) . Similarly, an analysis of CAC in 754 Women's Health Initiative (WHI) participants (32) and another small cohort of men (33) showed no association with previous random assignment to calcium supplement use. In addition, analyses of the effect of calcium supplementation on CVD events have had mixed results. An analysis of WHI calcium and vitamin D supplementation trial data by WHI investigators failed to support modestly higher CVD risk reported in a meta-analysis that used WHI data by Bolland et al (6, 10) . A 2010 meta-analysis of several randomized trials also showed no significant change in risk of CVD events for subjects randomly assigned to receive calcium supplementation (36) .
Initial concerns about negative CVD impacts of calcium supplements were raised by a randomized clinical trial from New Zealand of calcium supplementation (1000 mg/d) that reported a modest increase in MI risk in women who were taking calcium supplements (8) . This increase in MI risk was replicated in subsequent meta-analyses (9, 10) . A similar increase in MI risk with calcium supplement use was also seen in a recent prospective study of German men and women (11) , with a study from the United States that also showed increased risk of CVD death in men who were using calcium supplements (12) . However, these reports did have limitations. For example, in the initial report by TABLE 3 Associations between all-cause and CVD mortality and total, dietary, and supplemental calcium intakes Analysis was performed by using Cox proportional hazards regression. Calcium intake from supplements was considered as an ordinal variable [divided into milligram-intake ranges (0, 1-500, and
.500 mg)].
Model 1 was adjusted for age and total energy intake. Model 2 was adjusted as for model 1 and for BMI (in kg/m 2 ), smoking (never, past, or current), any alcohol consumption, energy-adjusted total vitamin D intake from diet and supplements (IU), use of lipid-lowering medications, and, in women, menopause status and estrogen use. For model 2, if the dietary calcium intake quartile was the main effect, the model was further adjusted for calcium intake from supplements (mg). For model 2, if tertiles of calcium intake from supplements were the main effect, the model was further adjusted for energy-adjusted dietary calcium (mg). CVD, cardiovascular disease.
Bolland et al (8) , the reported association was no longer significant when events that were not self-reported by participants but, instead, were sourced through a national hospital admissions database and death certificate review were included in an analysis with verified self-reported events. In both the original trial report (8) and larger subsequent meta-analyses by Bolland et al (9, 10) , studies included were originally designed to assess effects of calcium on bone density and fracture, with CVD outcomes considered only in secondary analyses. Additional problems with reports that calcium supplements increase risk of CVD events have been reviewed previously (37, 38) . In this study, we did not observe any negative CVD impacts of differing calcium intakes from diet and supplements in contrast to some previous reports (8) (9) (10) (11) (12) . Instead, calcium supplement use was associated with lower all-cause mortality risk in women. The association may have been due to a selection bias in terms of which participants in our cross-sectional analysis chose to take calcium supplements. Previous research has shown that individuals taking dietary supplements tend to have higher socioeconomic status, education levels, and physical activity (39, 40) . However, our results were essentially unchanged on additional adjustment for educational attainment (HR for all-cause mortality: 0.63; 95% CI: 0.43, 0.93; P = 0.02), which suggested other factors may have been responsible. Positive impacts of calcium supplements in women, notably increased BMD and prevention of fractures, may have led to the observed protective effect (6) . Our finding of a slight protective effect for all-cause mortality for women who were taking calcium supplements was also not unprecedented. A large cross-sectional study showed slightly lower risk of CVD and all-cause mortality in women who were taking calcium supplements in models adjusted for demographic and health-status covariates (41), which suggested a protective effect independent of socioeconomic status, and a Canadian study also showed reduced mortality risk in women who were using calcium supplements #1000 mg/d (42) .
Strengths of the current analysis included the study population with T2D, a group with elevated risk of CVD and fracture, comprehensive data for the analysis of vascular calcified plaque in multiple beds, and a long-term mortality follow-up of mean (6SD) 9.4 6 5.0 y. Limitations of our cross-sectional analysis included the concurrent measurement of calcium intake from diet and supplements and vascular calcification; if a participant's dietary habits or supplement use had recently changed, impacts may not yet have been observed on vascular calcified plaque. However, our failure to find higher subsequent mortality risk supported our baseline finding of no association of calcium intake with vascular calcification because vascular calcified plaque has been shown to be a strong predictor of mortality risk in our cohort (25, 26) .
In conclusion, in our analysis of calcium intake from diet and supplements in patients with T2D, we did not observe any significant associations between calcium intake and multiple measures of vascular calcified plaque, including CAC, CarCP, and AACP. We also observed no higher risk of all-cause or CVD mortality in individuals who were taking calcium supplements. We observed a modest association of an increased use of calcium supplements with lower risk of all-cause mortality in women. Our data do not support a significant association between differing calcium intakes from diet or supplements and CVD risk in individuals with T2D.
